Industry Strength Score
54/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
CYTEIR THERAPEUTICS INC (CYT) Stock Price & Overview
NASDAQ:CYT • US23284P1030
Current stock price
3.02 USD
-0.07 (-2.27%)
At close:
3.1 USD
+0.08 (+2.65%)
After Hours:
The current stock price of CYT is 3.02 USD. Today CYT is down by -2.27%. In the past month the price decreased by -2.89%. In the past year, price increased by 81.93%.
CYT Key Statistics
52-Week Range1.65 - 3.19
Current CYT stock price positioned within its 52-week range.
1-Month Range2.99 - 3.15
Current CYT stock price positioned within its 1-month range.
- Market Cap
- 108.72M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.30
- Dividend Yield
- N/A
CYT Stock Performance
Today
-2.27%
1 Week
-2.89%
1 Month
-2.89%
3 Months
-2.27%
Longer-term
6 Months +7.86%
1 Year +81.93%
2 Years -19.89%
3 Years N/A
5 Years N/A
10 Years N/A
CYT Stock Chart
CYT Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CYT. When comparing the yearly performance of all stocks, CYT is one of the better performing stocks in the market, outperforming 90.36% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
CYT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CYT. CYT has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CYT Earnings
Next Earnings DateN/A
Last Earnings DateMar 13, 2024
PeriodQ3 / 2023
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
CYT Forecast & Estimates
8 analysts have analysed CYT and the average price target is 3.06 USD. This implies a price increase of 1.32% is expected in the next year compared to the current price of 3.02.
Analysts
Analysts45
Price Target3.06 (1.32%)
EPS Next Y16.09%
Revenue Next YearN/A
CYT Financial Highlights
Over the last trailing twelve months CYT reported a non-GAAP Earnings per Share(EPS) of -1.3. The EPS increased by 31.88% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-33.21M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.35% | ||
| ROE | -26.57% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%67.74%
Sales Q2Q%N/A
EPS 1Y (TTM)31.88%
Revenue 1Y (TTM)N/A
CYT Ownership
Ownership
Inst Owners6.83%
Shares36.00M
Float33.61M
Ins Owners25.99%
Short Float %N/A
Short RatioN/A
CYT Industry Overview
CYT operates in the Biotechnology sub-industry within the Health Care sector. This group contains 412 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 412
- New Highs
- 4.6%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.9%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.1
CYT Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CYT
Company Profile
Cyteir Therapeutics, Inc.is a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. The company is headquartered in Lexington, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2021-06-18. The firm is focused on developing of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor (MCT) inhibitor, initially evaluated in a phase I/II study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard of care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy. Its CYT-0851 is also in development in combination with capecitabine and gemcitabine in a Phase I/II clinical study, including patients with advanced ovarian cancer.
Company Info
IPO: 2021-06-18
CYTEIR THERAPEUTICS INC
99 Hayden Avenue, Building B, Suite 450
Lexington MASSACHUSETTS US
CEO: Markus Renschler
Employees: 46
Phone: 18572854140
CYTEIR THERAPEUTICS INC / CYT FAQ
Can you describe the business of CYTEIR THERAPEUTICS INC?
Cyteir Therapeutics, Inc.is a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. The company is headquartered in Lexington, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2021-06-18. The firm is focused on developing of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor (MCT) inhibitor, initially evaluated in a phase I/II study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard of care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy. Its CYT-0851 is also in development in combination with capecitabine and gemcitabine in a Phase I/II clinical study, including patients with advanced ovarian cancer.
What is the stock price of CYTEIR THERAPEUTICS INC today?
The current stock price of CYT is 3.02 USD. The price decreased by -2.27% in the last trading session.
Does CYT stock pay dividends?
CYT does not pay a dividend.
How is the ChartMill rating for CYTEIR THERAPEUTICS INC?
CYT has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about CYTEIR THERAPEUTICS INC (CYT) stock?
8 analysts have analysed CYT and the average price target is 3.06 USD. This implies a price increase of 1.32% is expected in the next year compared to the current price of 3.02.
Can you provide the number of employees for CYTEIR THERAPEUTICS INC?
CYTEIR THERAPEUTICS INC (CYT) currently has 46 employees.
What is the market capitalization of CYT stock?
CYTEIR THERAPEUTICS INC (CYT) has a market capitalization of 108.72M USD. This makes CYT a Micro Cap stock.